Khin Ni A, Francis Gail, Mulinde Jean, Grandinetti Cheryl, Skeete Rachel, Yu Bei, Ayalew Kassa, Cho Seongeun-Julia, Fisher Andrew, Kleppinger Cynthia, Ayala Ruben, Bonapace Charles, Dasgupta Arindam, Kronstein Phillip D, Vinter Stephen
Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Inspection, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.
Clin Pharmacol Ther. 2020 Nov;108(5):949-963. doi: 10.1002/cpt.1794. Epub 2020 Mar 28.
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials. Regulatory agencies conduct GCP inspections to verify the integrity of data generated in clinical trials and to assure the protection of human research subjects, in addition to ensuring that clinical trials are conducted according to the applicable regulations. The first joint GCP workshop of the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA-UK) was held in October 2018 and provided the agencies' perspectives on the importance of data quality management practices on data integrity. Regulatory perspectives on data blinding to minimize introduction of bias, and the role of audit trails in assessing data integrity in global clinical trials were discussed. This paper summarizes considerations of both agencies on these topics, along with case examples.
《药物临床试验质量管理规范》(GCP)是一项用于设计、实施、记录和报告临床试验的国际伦理与科学质量标准。监管机构开展GCP检查,以核实临床试验所产生数据的完整性,并确保对人类研究受试者的保护,同时确保临床试验依据适用法规进行。美国食品药品监督管理局(FDA)药品评价和研究中心(CDER)与英国药品和医疗产品监管局(MHRA-UK)于2018年10月联合举办了首届GCP研讨会,会上介绍了两机构对于数据质量管理措施对数据完整性的重要性的观点。会议还讨论了监管机构对于使偏差最小化的数据盲法以及审计追踪在评估全球临床试验数据完整性中的作用的观点。本文总结了两机构在这些议题上的考量,并列举了案例。